<!DOCTYPE html>
<html lang="en" data-theme="light">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Cardiovascular Drugs - Pharmacology and Pharmacotherapeutics</title>
    
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">
    
    <link rel="stylesheet" href="../styles/main.css">
    
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams'
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <a href="#main-content" class="skip-link">Skip to main content</a>
    
    <div class="reading-progress-container">
        <div class="reading-progress-bar" id="reading-progress"></div>
    </div>

    <button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode">
        <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
        <span class="theme-toggle-icon dark-icon">üåô</span>
    </button>

    <!-- Floating Table of Contents -->
    <div class="floating-toc" id="floating-toc">
        <div class="floating-toc-header">
            <span>üìë</span>
            <span>Contents</span>
        </div>
        <ul class="floating-toc-list">
            <!-- JS will populate this -->
        </ul>
    </div>

    <div class="page-wrapper">
        <div class="container">
            <article class="document-article">
                <header class="document-header">
                    <div class="header-badge">
                        <span>‚ù§Ô∏è</span>
                        <span>Section VII</span>
                    </div>
                    <h1 class="document-title">Cardiovascular Drugs</h1>
                    <div class="title-meta">
                        <div class="meta-item">
                            <span>üìö</span>
                            <span>Arrhythmias, Angina, Hypertension, Heart Failure & Shock</span>
                        </div>
                        <div class="meta-item">
                            <span>‚è±Ô∏è</span>
                            <span>180 min read</span>
                        </div>
                    </div>
                </header>

                <main id="main-content" class="content-wrapper">
                    <!-- START: Chapter 28 -->
                    <section class="content-section" id="chapter-28">
                        <div class="section-header">
                            <div class="section-number">28</div>
                            <h2 class="section-title">
                                <span class="title-icon">üíì</span>
                                Pharmacotherapy of Cardiac Arrhythmias
                            </h2>
                        </div>

                        <div class="content-card">
                            <p><strong>Cardiac arrhythmia</strong> is defined as disturbance of initiation or conduction of cardiac impulse. Anti-arrhythmic drugs are the drugs used to prevent or correct cardiac arrhythmias.</p>

                            <h3>Electrophysiology of Cardiac Tissue</h3>
                            <p>The cardiac cell is bounded by a lipoprotein membrane which has receptor channels crossing it. These are ion-selective membrane spanning proteins which permit passive movement of ions ($\mathrm{Na}^{+}, \mathrm{K}^{+}, \mathrm{Ca}^{++}$ and $\mathrm{Cl}^{-}$) down their electrochemical gradients during the open but not during the closed state of the channels.</p>

                            <figure class="content-figure" data-lightbox="true">
                                <div class="figure-image-wrapper">
                                    <img src="../assets/images/image-20251214-05ff7d4c.jpeg" 
                                         alt="Transmembrane action potential" 
                                         class="figure-image"
                                         loading="lazy">
                                    <div class="figure-overlay">
                                        <span class="overlay-icon">üîç</span>
                                        <span class="overlay-text">Click to enlarge</span>
                                    </div>
                                </div>
                                <figcaption class="figure-caption">Fig. 28.1: Relationship between transmembrane cationic fluxes, ECG recording and transmembrane action potential.</figcaption>
                            </figure>

                            <p><strong>Phases of Action Potential:</strong></p>
                            <ul>
                                <li><strong>Phase 0 (Rapid Depolarisation):</strong> Due to fast influx of $\mathrm{Na}^{+}$ through fast sodium channels.</li>
                                <li><strong>Phase 1 (Rapid Repolarisation):</strong> Transient, due to $\mathrm{K}^{+}$ outflow.</li>
                                <li><strong>Phase 2 (Plateau):</strong> Balance between $\mathrm{Ca}^{++}$ influx (slow channels) and $\mathrm{K}^{+}$ efflux. Corresponds to ST segment.</li>
                                <li><strong>Phase 3 (Rapid Repolarisation):</strong> Continued extrusion of $\mathrm{K}^{+}$. Corresponds to T wave.</li>
                                <li><strong>Phase 4 (Resting):</strong> Maintenance of resting potential by $\mathrm{Na}^{+}-\mathrm{K}^{+}$ ATPase pump. In pacemaker cells (SA/AV node), there is spontaneous diastolic depolarisation (slope of phase 4).</li>
                            </ul>

                            <h3>Mechanisms of Arrhythmias</h3>
                            <div class="grid grid-2">
                                <div class="grid-item">
                                    <h4>Disorders of Impulse Formation</h4>
                                    <p>Associated with spontaneous, irregular and rhythmic discharge from ectopic pacemaker activity (enhanced automaticity). Examples: Atrial tachycardia, atrial flutter, atrial fibrillation (AF).</p>
                                </div>
                                <div class="grid-item">
                                    <h4>Disorders of Impulse Conduction</h4>
                                    <p>Commonly referred to as <strong>re-entry disturbances</strong>. An impulse takes a circuitous route through depressed tissue and re-excites normal tissue. Examples: Ventricular tachycardia (VT), ventricular fibrillation (VF).</p>
                                </div>
                            </div>

                            <h3>Classification of Antiarrhythmic Drugs (Vaughan Williams)</h3>
                            
                            <div class="table-responsive">
                                <table class="comparison-table">
                                    <thead>
                                        <tr>
                                            <th>Class</th>
                                            <th>Mechanism</th>
                                            <th>Examples</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td><strong>Class I</strong></td>
                                            <td><strong>Fast Sodium Channel Blockers</strong> (Membrane Stabilisers)</td>
                                            <td></td>
                                        </tr>
                                        <tr>
                                            <td><em>IA</em></td>
                                            <td>Moderate Phase 0 depression, prolong repolarisation.</td>
                                            <td>Quinidine, Procainamide, Disopyramide</td>
                                        </tr>
                                        <tr>
                                            <td><em>IB</em></td>
                                            <td>Weak Phase 0 depression, shorten repolarisation.</td>
                                            <td>Lignocaine, Phenytoin, Mexiletine</td>
                                        </tr>
                                        <tr>
                                            <td><em>IC</em></td>
                                            <td>Marked Phase 0 depression, no effect on repolarisation.</td>
                                            <td>Flecainide, Propafenone</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Class II</strong></td>
                                            <td><strong>Beta Adrenergic Blockers</strong></td>
                                            <td>Propranolol, Esmolol, Metoprolol</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Class III</strong></td>
                                            <td><strong>Potassium Channel Blockers</strong> (Prolong repolarisation/APD)</td>
                                            <td>Amiodarone, Sotalol, Ibutilide, Dofetilide</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Class IV</strong></td>
                                            <td><strong>Calcium Channel Blockers</strong></td>
                                            <td>Verapamil, Diltiazem</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Class V</strong></td>
                                            <td><strong>Miscellaneous</strong></td>
                                            <td>Adenosine, Digoxin, Magnesium, Potassium</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>

                            <h3>Specific Drugs</h3>

                            <h4>Quinidine (Class IA)</h4>
                            <p><strong>Actions:</strong> Depresses automaticity, excitability, and conduction velocity. Prolongs ERP (Direct action). Has vagolytic (antimuscarinic) action which may enhance AV conduction (paradoxical tachycardia).</p>
                            <p><strong>ECG Changes:</strong> QT prolongation, QRS widening.</p>
                            <div class="callout callout--danger">
                                <div class="callout-header">
                                    <span class="callout-icon">‚ö†Ô∏è</span>
                                    <h4 class="callout-title">Adverse Reactions</h4>
                                </div>
                                <div class="callout-content">
                                    <ul>
                                        <li><strong>Cinchonism:</strong> Tinnitus, vertigo, blurred vision.</li>
                                        <li><strong>Cardiac Toxicity:</strong> Torsade de pointes (polymorphic VT), hypotension, AV block.</li>
                                        <li><strong>Drug Interactions:</strong> Increases plasma digoxin levels.</li>
                                    </ul>
                                </div>
                            </div>

                            <h4>Lignocaine (Lidocaine) (Class IB)</h4>
                            <p><strong>Actions:</strong> Selectively acts on diseased/ischemic myocardium. Shortens APD. No effect on AV conduction or hemodynamics. Given IV (high first pass metabolism).</p>
                            <p><strong>Uses:</strong> Drug of choice for <strong>ventricular arrhythmias</strong> (post-MI, digitalis-induced).</p>

                            <h4>Beta Blockers (Class II)</h4>
                            <p><strong>Propranolol, Metoprolol, Esmolol</strong> (Short acting, IV). Depress Phase 4 depolarisation. Useful in supraventricular tachyarrhythmias (SVT) associated with sympathetic overactivity.</p>

                            <h4>Amiodarone (Class III)</h4>
                            <p>Potent broad-spectrum antiarrhythmic. Has Class I, II, III and IV actions. Very long half-life (weeks).</p>
                            <p><strong>Uses:</strong> Recurrent VT/VF, Atrial Fibrillation (maintenance of sinus rhythm).</p>
                            <p><strong>Adverse Effects:</strong> Pulmonary fibrosis, Thyroid dysfunction (hypo/hyper), Corneal microdeposits, Photosensitivity, Hepatotoxicity.</p>

                            <h4>Calcium Channel Blockers (Class IV)</h4>
                            <p><strong>Verapamil, Diltiazem.</strong> Act on slow response tissues (SA/AV nodes). Slow AV conduction.</p>
                            <p><strong>Uses:</strong> PSVT (termination), Rate control in AF/Flutter.</p>

                            <h4>Adenosine</h4>
                            <p>Purine nucleoside. Activates $\mathrm{K}^{+}$ current (hyperpolarisation) in AV node. Ultra-short half-life (seconds). <strong>Drug of choice for terminating PSVT.</strong></p>

                            <div class="table-responsive">
                                <table class="comparison-table">
                                    <caption>Table 28.4: Drug treatment of cardiac arrhythmias (Summary)</caption>
                                    <thead>
                                        <tr>
                                            <th>Arrhythmia</th>
                                            <th>Acute/Emergency Treatment</th>
                                            <th>Chronic/Prophylactic Treatment</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td><strong>Sinus Bradycardia</strong></td>
                                            <td>Atropine</td>
                                            <td>Pacemaker</td>
                                        </tr>
                                        <tr>
                                            <td><strong>PSVT</strong></td>
                                            <td>Adenosine, Vagal maneuvers</td>
                                            <td>Verapamil, Beta blockers, Radiofrequency ablation</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Atrial Fibrillation</strong></td>
                                            <td>Rate control: Beta blockers, Verapamil, Digoxin<br>Rhythm control: DC Shock, Amiodarone</td>
                                            <td>Rate control: Beta blockers, Diltiazem<br>Rhythm control: Amiodarone<br><strong>Anticoagulation</strong> (Warfarin/Dabigatran)</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Ventricular Tachycardia</strong></td>
                                            <td>Lignocaine, Amiodarone, DC Shock</td>
                                            <td>Amiodarone, ICD (Implantable Cardioverter Defibrillator)</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Digitalis Induced</strong></td>
                                            <td>Lignocaine, Phenytoin, Digibind</td>
                                            <td>-</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Torsade de Pointes</strong></td>
                                            <td>Magnesium Sulfate</td>
                                            <td>Pacing</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>
                    </section>
                    <!-- END: Chapter 28 -->

                    <!-- START: Chapter 29 -->
                    <section class="content-section" id="chapter-29">
                        <div class="section-header">
                            <div class="section-number">29</div>
                            <h2 class="section-title">
                                <span class="title-icon">üíî</span>
                                Angina Pectoris, Acute MI and Peripheral Vascular Diseases
                            </h2>
                        </div>

                        <div class="content-card">
                            <p><strong>Ischemic Heart Disease (IHD)</strong> results from an imbalance between myocardial oxygen supply and demand. <strong>Angina Pectoris</strong> is the primary symptom.</p>

                            <h3>Classification of Angina</h3>
                            <ul>
                                <li><strong>Stable Angina:</strong> Pain on exertion, relieved by rest/nitrates. Fixed narrowing of coronaries.</li>
                                <li><strong>Unstable Angina (UA):</strong> Pain at rest or worsening pattern. Pre-infarction state.</li>
                                <li><strong>Variant (Prinzmetal) Angina:</strong> Pain at rest due to coronary vasospasm. ST elevation during attack.</li>
                            </ul>

                            <h3>Drug Classes Used in Angina</h3>

                            <h4>1. Organic Nitrates</h4>
                            <p><strong>Mechanism:</strong> Release Nitric Oxide (NO) $\rightarrow$ increases cGMP $\rightarrow$ vascular smooth muscle relaxation.</p>
                            <p><strong>Actions:</strong></p>
                            <ul>
                                <li><strong>Venodilatation (Preload reduction):</strong> Main effect. Reduces venous return and ventricular wall tension.</li>
                                <li><strong>Arteriolar dilatation (Afterload reduction):</strong> Lesser extent.</li>
                                <li><strong>Coronary dilatation:</strong> Dilates large epicardial vessels and collaterals.</li>
                            </ul>
                            <p><strong>Preparations:</strong></p>
                            <ul>
                                <li><strong>Glyceryl Trinitrate (Nitroglycerine/NTG):</strong> Sublingual (0.5 mg) for acute attack. Action in 1-2 mins. Also transdermal/IV.</li>
                                <li><strong>Isosorbide Dinitrate/Mononitrate:</strong> Longer acting oral forms for prophylaxis.</li>
                            </ul>
                            <p><strong>Adverse Effects:</strong> Headache (very common), flushing, hypotension, tachycardia. <strong>Tolerance</strong> develops on continuous use (needs nitrate-free interval of 8-10 hrs/day).</p>

                            <h4>2. Beta-Adrenergic Blockers</h4>
                            <p><strong>Atenolol, Metoprolol.</strong> Reduce heart rate, contractility, and BP $\rightarrow$ Reduce Myocardial $O_2$ demand. Used for prophylaxis of stable angina. <strong>Contraindicated in Variant Angina</strong> (may worsen spasm).</p>

                            <h4>3. Calcium Channel Blockers (CCB)</h4>
                            <p>Block L-type $\mathrm{Ca}^{++}$ channels.</p>
                            <ul>
                                <li><strong>Verapamil/Diltiazem:</strong> Cardiac depressants (Rate/Contractility $\downarrow$). Vasodilators.</li>
                                <li><strong>Dihydropyridines (Nifedipine, Amlodipine):</strong> Potent vasodilators (Afterload $\downarrow$, Coronary flow $\uparrow$). Nifedipine may cause reflex tachycardia.</li>
                            </ul>
                            <p><strong>Uses:</strong> Stable angina (especially if Beta blockers contraindicated), Variant angina (Drug of Choice).</p>

                            <h4>4. Potassium Channel Activators</h4>
                            <p><strong>Nicorandil:</strong> Opens $K_{ATP}$ channels (vasodilation) + NO donor. Useful in refractory angina.</p>

                            <h4>5. Others</h4>
                            <p><strong>Trimetazidine:</strong> Metabolic modulator (pFOX inhibitor). Improves myocardial energy utilisation.</p>
                            <p><strong>Ranolazine:</strong> Inhibits late Sodium current. Prevents Calcium overload.</p>
                            <p><strong>Ivabradine:</strong> Selectively inhibits $I_f$ current in SA node. Reduces heart rate without affecting contractility.</p>

                            <h3>Management of Acute Myocardial Infarction (AMI)</h3>
                            <p><strong>Goals:</strong> Pain relief, restoration of flow (reperfusion), prevention of complications/death.</p>
                            <div class="callout callout--info">
                                <div class="callout-header">
                                    <span class="callout-icon">üöë</span>
                                    <h4 class="callout-title">Immediate Treatment Protocol (MONA)</h4>
                                </div>
                                <div class="callout-content">
                                    <ul>
                                        <li><strong>M</strong>orphine: IV for pain and anxiety. Also reduces preload.</li>
                                        <li><strong>O</strong>xygen: To correct hypoxemia.</li>
                                        <li><strong>N</strong>itroglycerine: Sublingual/IV to reduce preload and ischemic pain.</li>
                                        <li><strong>A</strong>spirin: Chewed (160-325 mg) immediately. Antiplatelet effect.</li>
                                    </ul>
                                </div>
                            </div>

                            <p><strong>Reperfusion Therapy:</strong></p>
                            <ul>
                                <li><strong>Thrombolytics (Fibrinolytics):</strong> Streptokinase, Alteplase (tPA). Effective in STEMI if given early (within 12 hrs, best within 3 hrs). Risk of hemorrhage.</li>
                                <li><strong>Primary PCI (Angioplasty):</strong> Preferred if available.</li>
                            </ul>

                            <p><strong>Adjunctive Therapy:</strong></p>
                            <ul>
                                <li><strong>Beta-blockers:</strong> IV/Oral. Reduce infarct size, arrhythmias, and mortality.</li>
                                <li><strong>ACE Inhibitors:</strong> Reduce ventricular remodeling and mortality. Started within 24 hrs.</li>
                                <li><strong>Antiplatelets:</strong> Clopidogrel/Prasugrel added to Aspirin.</li>
                                <li><strong>Anticoagulants:</strong> Heparin/LMWH.</li>
                                <li><strong>Statins:</strong> High dose Atorvastatin.</li>
                            </ul>

                            <h3>Peripheral Vascular Diseases</h3>
                            <p><strong>Cilostazol:</strong> PDE3 inhibitor. Vasodilator + Antiplatelet. Used for intermittent claudication.</p>
                            <p><strong>Pentoxifylline:</strong> Hemorrheologic agent (reduces blood viscosity).</p>
                        </div>
                    </section>
                    <!-- END: Chapter 29 -->

                    <!-- START: Chapter 30 -->
                    <section class="content-section" id="chapter-30">
                        <div class="section-header">
                            <div class="section-number">30</div>
                            <h2 class="section-title">
                                <span class="title-icon">ü©∫</span>
                                Pharmacotherapy of Hypertension
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Hypertension is defined as BP $> 140/90$ mmHg. It is a major risk factor for stroke, MI, heart failure, and renal failure.</p>

                            <h3>Classification of Antihypertensive Drugs</h3>
                            <div class="grid grid-2">
                                <div class="grid-item">
                                    <h4>1. Diuretics</h4>
                                    <p><strong>Thiazides (Hydrochlorothiazide, Chlorthalidone):</strong> First line for many. Reduce plasma volume and PVR. Low dose (12.5-25 mg) preferred.</p>
                                    <p><strong>Loop Diuretics (Furosemide):</strong> Used in renal failure or resistant hypertension.</p>
                                    <p><strong>K+ Sparing (Spironolactone):</strong> Used as add-on.</p>
                                </div>
                                <div class="grid-item">
                                    <h4>2. RAAS Inhibitors</h4>
                                    <p><strong>ACE Inhibitors (Captopril, Enalapril, Ramipril):</strong> Inhibit Angiotensin II formation and bradykinin breakdown. Drug of choice in Diabetes, Heart Failure, CKD. Side effects: Dry cough, Angioedema, Hyperkalemia.</p>
                                    <p><strong>ARBs (Losartan, Telmisartan):</strong> Block AT1 receptors. Similar benefits to ACEI but no cough.</p>
                                    <p><strong>Renin Inhibitors:</strong> Aliskiren.</p>
                                </div>
                                <div class="grid-item">
                                    <h4>3. Calcium Channel Blockers</h4>
                                    <p><strong>Dihydropyridines (Amlodipine, Nifedipine):</strong> Vasodilators. Good for elderly and isolated systolic HTN. Side effect: Ankle edema.</p>
                                    <p><strong>Non-DHP (Verapamil, Diltiazem):</strong> Reduce heart rate and contractility.</p>
                                </div>
                                <div class="grid-item">
                                    <h4>4. Sympatholytics</h4>
                                    <p><strong>Beta Blockers (Atenolol, Metoprolol):</strong> Reduce CO and renin release. Preferred in young patients and those with IHD.</p>
                                    <p><strong>Alpha Blockers (Prazosin):</strong> Vasodilators. Useful in BPH.</p>
                                    <p><strong>Central Sympatholytics (Clonidine, Methyldopa):</strong> Stimulate central $\alpha_2$ receptors. Methyldopa is safe in pregnancy.</p>
                                </div>
                            </div>

                            <h3>Vasodilators</h3>
                            <ul>
                                <li><strong>Hydralazine:</strong> Direct arteriolar vasodilator. Used in severe HTN/Pregnancy. Causes reflex tachycardia (give with beta blocker) and Lupus-like syndrome.</li>
                                <li><strong>Minoxidil:</strong> Potent arteriolar vasodilator (K+ channel opener). Used in refractory HTN. Side effect: Hypertrichosis (hair growth).</li>
                                <li><strong>Sodium Nitroprusside:</strong> Dilates both arterioles and veins. Releases NO. Used IV for <strong>Hypertensive Emergencies</strong>. Action instantaneous. Toxicity: Thiocyanate/Cyanide accumulation.</li>
                            </ul>

                            <h3>Management Guidelines</h3>
                            <p><strong>Step 1:</strong> Lifestyle modifications (Diet, Exercise, Salt restriction).</p>
                            <p><strong>Step 2:</strong> Drug Monotherapy (A, C, D) - ACEI/ARB, CCB, or Diuretic. Beta blockers not first line for uncomplicated HTN.</p>
                            <p><strong>Step 3:</strong> Combination therapy (e.g., ACEI + CCB, or ARB + Diuretic).</p>
                            <div class="callout callout--tip">
                                <div class="callout-header">
                                    <span class="callout-icon">ü§∞</span>
                                    <h4 class="callout-title">Hypertension in Pregnancy</h4>
                                </div>
                                <div class="callout-content">
                                    <p><strong>Preferred Drugs:</strong> Methyldopa, Labetalol, Nifedipine, Hydralazine.<br>
                                    <strong>Contraindicated:</strong> ACE Inhibitors, ARBs, Diuretics (generally).</p>
                                </div>
                            </div>

                            <h3>Pulmonary Hypertension</h3>
                            <p>Treatment includes:</p>
                            <ul>
                                <li><strong>Endothelin Antagonists:</strong> Bosentan, Ambrisentan.</li>
                                <li><strong>PDE-5 Inhibitors:</strong> Sildenafil, Tadalafil.</li>
                                <li><strong>Prostacyclin Analogues:</strong> Epoprostenol, Iloprost.</li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: Chapter 30 -->

                    <!-- START: Chapter 31 -->
                    <section class="content-section" id="chapter-31">
                        <div class="section-header">
                            <div class="section-number">31</div>
                            <h2 class="section-title">
                                <span class="title-icon">üìâ</span>
                                Pharmacotherapy of Heart Failure
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Heart failure (HF) is the inability of the heart to pump sufficient blood to meet metabolic needs. Compensatory mechanisms include: Sympathetic stimulation, RAAS activation (Fluid retention, vasoconstriction), and Ventricular remodeling (Hypertrophy/Dilatation).</p>

                            <h3>Drugs for Heart Failure</h3>

                            <h4>1. Drugs Improving Survival (Neurohumoral Blockade)</h4>
                            <ul>
                                <li><strong>ACE Inhibitors / ARBs:</strong> Cornerstone of therapy. Reverse remodeling, reduce preload/afterload.</li>
                                <li><strong>Beta Blockers:</strong> (Metoprolol succinate, Carvedilol, Bisoprolol). Block sympathetic toxicity. Start low dose.</li>
                                <li><strong>Aldosterone Antagonists:</strong> (Spironolactone, Eplerenone). Prevent fibrosis. Added in severe HF.</li>
                            </ul>

                            <h4>2. Drugs for Symptomatic Relief</h4>
                            <ul>
                                <li><strong>Diuretics:</strong> (Furosemide). Relieve congestion/edema. Do not improve survival.</li>
                                <li><strong>Digoxin:</strong> Positive inotrope (inhibits $\mathrm{Na}^{+}/\mathrm{K}^{+}$ ATPase). Increases contractility, slows heart rate (vagal).</li>
                            </ul>

                            <div class="callout callout--warning">
                                <div class="callout-header">
                                    <span class="callout-icon">‚ò¢Ô∏è</span>
                                    <h4 class="callout-title">Digoxin Toxicity</h4>
                                </div>
                                <div class="callout-content">
                                    <p>Narrow therapeutic index. Enhanced by <strong>Hypokalemia</strong>.<br>
                                    <strong>Signs:</strong> Anorexia, Nausea, Vomiting, Visual disturbances (Yellow vision), Arrhythmias (Bigeminy, AV block, VT).<br>
                                    <strong>Treatment:</strong> Stop drug, correct K+, Atropine (for bradycardia), Lignocaine (for VT), Digibind (antibodies).</p>
                                </div>
                            </div>

                            <h4>3. Acute Heart Failure (Acute LVF) Management</h4>
                            <ul>
                                <li><strong>Diuretics:</strong> IV Furosemide (Lasix).</li>
                                <li><strong>Vasodilators:</strong> Nitroglycerine IV or Nitroprusside.</li>
                                <li><strong>Inotropes:</strong> Dobutamine, Dopamine, Milrinone (PDE3 inhibitor), Levosimendan (Calcium sensitiser).</li>
                                <li><strong>Oxygen/Morphine.</strong></li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: Chapter 31 -->

                    <!-- START: Chapter 32 -->
                    <section class="content-section" id="chapter-32">
                        <div class="section-header">
                            <div class="section-number">32</div>
                            <h2 class="section-title">
                                <span class="title-icon">‚ö°</span>
                                Pharmacotherapy of Shock
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Shock is a state of inadequate tissue perfusion. Types: Hypovolemic, Cardiogenic, Septic (Distributive), Anaphylactic, Neurogenic.</p>

                            <h3>General Management</h3>
                            <ul>
                                <li><strong>Fluid Replacement:</strong> Crystalloids (Normal Saline, Ringer Lactate) or Colloids. Critical for hypovolemic and septic shock.</li>
                                <li><strong>Oxygenation.</strong></li>
                                <li><strong>Acidosis Correction:</strong> Sodium bicarbonate (if severe).</li>
                            </ul>

                            <h3>Vasoactive Drugs (Inotropes/Vasopressors)</h3>
                            <div class="table-responsive">
                                <table class="comparison-table">
                                    <thead>
                                        <tr>
                                            <th>Drug</th>
                                            <th>Receptor Action</th>
                                            <th>Indication</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td><strong>Dopamine</strong></td>
                                            <td>Low dose: D1 (Renal vasodilation)<br>Med dose: $\beta_1$ (Inotropic)<br>High dose: $\alpha_1$ (Vasoconstriction)</td>
                                            <td>Cardiogenic/Septic shock (with oliguria).</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Dobutamine</strong></td>
                                            <td>Selective $\beta_1$ agonist</td>
                                            <td>Cardiogenic shock (Pump failure).</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Noradrenaline</strong></td>
                                            <td>$\alpha > \beta_1$</td>
                                            <td>Septic shock (Vasodilatory shock). Potent vasoconstrictor.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Adrenaline</strong></td>
                                            <td>$\alpha + \beta$</td>
                                            <td><strong>Anaphylactic shock</strong> (Drug of choice).</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Phenylephrine</strong></td>
                                            <td>Pure $\alpha_1$</td>
                                            <td>Neurogenic shock.</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>
                    </section>
                    <!-- END: Chapter 32 -->
                    
                    <aside class="key-points-section" role="region" aria-labelledby="key-points-title">
                        <div class="key-points-wrapper">
                            <div class="key-points-header">
                                <span class="key-points-icon">‚≠ê</span>
                                <h3 id="key-points-title" class="key-points-title">Section VII Key Points</h3>
                            </div>
                            <ul class="key-points-list">
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Adenosine</strong> is the drug of choice for paroxysmal supraventricular tachycardia (PSVT).</p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Lignocaine</strong> is effective only for ventricular arrhythmias.</p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Nitrates</strong> reduce preload (venodilation) and are the mainstay for angina symptom relief.</p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Beta-blockers</strong> and <strong>ACE inhibitors</strong> improve survival in heart failure and post-MI patients.</p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Digoxin toxicity</strong> is precipitated by hypokalemia; manifestations include yellow vision and bigeminy.</p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Adrenaline</strong> is the life-saving drug for anaphylactic shock.</p>
                                </li>
                            </ul>
                        </div>
                    </aside>
                </main>

                <nav class="document-nav">
                    <div class="nav-container">
                        <a href="section-06.html" class="nav-button nav-button--large nav-button--previous">
                            <div class="nav-label">Previous</div>
                            <div class="nav-title">Section VI: Respiratory Drugs</div>
                        </a>
                        
                        <div class="document-progress">
                            <div class="progress-indicator">
                                <span>7</span>
                                <span class="progress-separator">/</span>
                                <span>16</span>
                            </div>
                        <a href="../index.html" class="nav-button nav-button--large">
                            <div class="nav-label">Go to</div>
                            <div class="nav-title">Index</div>
                        </a>
                            <div class="progress-bar-container">
                                <div class="progress-bar-fill" style="width: 43.75%;"></div>
                            </div>
                            <div class="progress-label">Section 7 of 16</div>
                        </div>
                        
                        <a href="section-08.html" class="nav-button nav-button--large nav-button--next">
                            <div class="nav-label">Next</div>
                            <div class="nav-title">Section VIII: Blood Drugs</div>
                        </a>
                    </div>
                </nav>
            </article>
        </div>
    </div>

    <!-- Lightbox Modal -->
    <div class="lightbox-modal" id="lightbox-modal" role="dialog" aria-modal="true" aria-label="Image viewer" hidden>
        <div class="lightbox-backdrop"></div>
        <div class="lightbox-content">
            <button class="lightbox-close" aria-label="Close image viewer">√ó</button>
            <img class="lightbox-image" src="" alt="">
            <p class="lightbox-caption"></p>
        </div>
    </div>

    <script src="../js/theme.js"></script>
    <script src="../js/navigation.js"></script>
    <script src="../js/interactions.js"></script>
</body>
</html>